NASDAQ:IGMS IGM Biosciences (IGMS) Stock Price, News & Analysis → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free IGMS Stock Alerts $9.27 0.00 (0.00%) (As of 02:24 PM ET) Add Compare Share Share Today's Range$9.18▼$9.8450-Day Range$6.75▼$12.5152-Week Range$3.81▼$17.70Volume96,663 shsAverage Volume283,624 shsMarket Capitalization$544.98 millionP/E RatioN/ADividend YieldN/APrice Target$17.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get IGM Biosciences alerts: Email Address IGM Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside93.0% Upside$17.89 Price TargetShort InterestBearish29.87% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.36Based on 13 Articles This WeekInsider TradingAcquiring Shares$3.17 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.22) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.98 out of 5 starsMedical Sector579th out of 2,771 stocksPharmaceutical Preparations Industry239th out of 1,288 stocks 3.3 Analyst's Opinion Consensus RatingIGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIGM Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about IGM Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.87% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 21.6, which indicates bearish sentiment.Change versus previous monthShort interest in IGM Biosciences has recently increased by 18.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for IGM Biosciences is -1.08. Previous Next 2.4 News and Social Media Coverage News SentimentIGM Biosciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for IGM Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have bought 3,814.50% more of their company's stock than they have sold. Specifically, they have bought $3,167,890.00 in company stock and sold $80,927.00 in company stock.Percentage Held by Insiders56.91% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IGM Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IGM Biosciences are expected to grow in the coming year, from ($3.22) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IGM Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyGuard Against the Coming Financial UpheavalAmerica’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. About IGM Biosciences Stock (NASDAQ:IGMS)IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Read More IGMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGMS Stock News HeadlinesMay 13 at 3:56 AM | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Rating Reiterated by WedbushMay 12 at 3:33 AM | seekingalpha.comIGM Biosciences: Unlikely To Move The Needle Again In 2024May 10, 2024 | finance.yahoo.comIGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)May 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on IGM Biosciences (IGMS)May 9, 2024 | investorplace.comIGMS Stock Earnings: IGM Biosciences Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comIGM Biosciences to Present at the 2024 RBCCM Global Healthcare ConferenceMay 4, 2024 | americanbankingnews.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 2, 2024 | markets.businessinsider.comIGM Biosciences Upgraded to Buy: What Does It Mean for the Stock?April 19, 2024 | finance.yahoo.comIGM Biosciences Insiders Placed Bullish Bets Worth US$992.2kApril 18, 2024 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About IGM BiosciencesApril 18, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)April 17, 2024 | bizjournals.comBig drugmaker's cancer rollback trickles down to another Bay Area companyApril 17, 2024 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Refocusing of Sanofi CollaborationApril 17, 2024 | markets.businessinsider.comWhy IGM Biosciences Is Rising In Pre-market?April 17, 2024 | finance.yahoo.comIGM Biosciences Announces Refocusing of Sanofi CollaborationApril 17, 2024 | globenewswire.comIGM Biosciences Announces Refocusing of Sanofi CollaborationApril 10, 2024 | globenewswire.comIGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 8, 2024 | finance.yahoo.comIGM Biosciences, Inc. (IGMS)March 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)March 15, 2024 | finance.yahoo.comIGMS Apr 2024 22.500 callMarch 9, 2024 | finance.yahoo.comIGM Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 9, 2024 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 8, 2024 | investorplace.comIGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023See More Headlines Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IGMS CUSIPN/A CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees224Year Founded2010Price Target and Rating Average Stock Price Target$17.89 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+93.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-246,420,000.00 Net Margins-11,255.25% Pretax Margin-11,227.17% Return on Equity-108.07% Return on Assets-54.01% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$2.13 million Price / Sales255.86 Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book2.68Miscellaneous Outstanding Shares58,790,000Free Float25,331,000Market Cap$544.98 million OptionableOptionable Beta0.27 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Fred M. Schwarzer J.D. (Age 71)CEO, President & Director Comp: $977.66kDr. Bruce A. Keyt Ph.D. (Age 70)Chief Scientific Officer Comp: $692.95kDr. Chris H. Takimoto FACP (Age 65)M.D., Ph.D., Chief Medical Officer Comp: $684.95kMr. Misbah Tahir (Age 48)Chief Financial Officer Comp: $957.6kMr. TS HarigopalSenior Vice President of Group OperationsMr. Steven Weber (Age 48)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Paul C. GraffagninoSenior Vice President of Legal AffairsMs. Suzette Tauber (Age 60)Chief Human Resources Officer Dr. Angus M. Sinclair Ph.D.Senior Vice President of Immuno-OncologyDr. Lisa L. Decker Ph.D. (Age 54)Chief Business Officer Comp: $528.18kMore ExecutivesKey CompetitorsArriVent BioPharmaNASDAQ:AVBPAerovate TherapeuticsNASDAQ:AVTEPhathom PharmaceuticalsNASDAQ:PHATAvid BioservicesNASDAQ:CDMOCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 43,491 shares on 5/10/2024Ownership: 1.452%Susquehanna Fundamental Investments LLCBought 27,731 shares on 5/7/2024Ownership: 0.047%Bros. Advisors Lp BakerBought 97,473 shares on 3/28/2024Total: $937,690.26 ($9.62/share)Bros. Advisors Lp BakerBought 270,000 shares on 3/26/2024Total: $2.23 M ($8.26/share)Fred SchwarzerSold 4,765 sharesTotal: $47,078.20 ($9.88/share)View All Insider TransactionsView All Institutional Transactions IGMS Stock Analysis - Frequently Asked Questions Should I buy or sell IGM Biosciences stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IGMS shares. View IGMS analyst ratings or view top-rated stocks. What is IGM Biosciences' stock price target for 2024? 8 Wall Street research analysts have issued 1-year price targets for IGM Biosciences' stock. Their IGMS share price targets range from $8.00 to $25.00. On average, they predict the company's stock price to reach $17.89 in the next twelve months. This suggests a possible upside of 93.0% from the stock's current price. View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts. How have IGMS shares performed in 2024? IGM Biosciences' stock was trading at $8.31 at the beginning of the year. Since then, IGMS stock has increased by 11.6% and is now trading at $9.27. View the best growth stocks for 2024 here. When is IGM Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our IGMS earnings forecast. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $0.05. The business had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.95 million. IGM Biosciences had a negative trailing twelve-month return on equity of 108.07% and a negative net margin of 11,255.25%. What ETFs hold IGM Biosciences' stock? ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET). When did IGM Biosciences IPO? IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are IGM Biosciences' major shareholders? IGM Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.45%) and Susquehanna Fundamental Investments LLC (0.05%). Insiders that own company stock include Bros Advisors Lp Baker, Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Steven Weber. View institutional ownership trends. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IGMS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
